Genti in the News

July 01, 2025

GentiBio Receives FDA Orphan Drug Designation for GNTI-122 for the Treatment of Recently Diagnosed Type 1 Diabetes
April 29, 2025

GentiBio to Showcase Groundbreaking Advances in Engineered Regulatory T Cell Therapies at ASGCT and AAI 2025 Annual Meetings
September 30, 2024

GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
May 01, 2024

GentiBio to Unveil Cutting-Edge Research at ASGCT Conference
March 23, 2024

GentiBio Announces Preclinical Data for GNTI-122, GentiBio’s Lead Candidate, an Autologous, Antigen-Specific Engineered T Regulatory Cell (EngTregs) for the Treatment of Newly Diagnosed and At-Risk Type 1 Diabetes (T1D)
November 15, 2022

GentiBio Named A BioSpace 2023 Best Places to Work
October 11, 2022

GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
September 15, 2022

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
August 10, 2022

GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
June 24, 2022

GentiBio Announces Participation in Two Upcoming Investor Conferences
January 14, 2022

Rapport: To succeed, we must prepare ourselves for failure
January 06, 2022

Biospace: Top Life Sciences Startups to Watch in 2022
August 11, 2021

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
July 15, 2021

GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership
October 28, 2020

GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies
August 05, 2020

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases